On 11 February 2020, the International Committee for the Classification of Viruses namedthe disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia(coronavirus disease 2019, COVID-19). Due to the characteristics of livermicrocirculation disturbance and immune function disorder in patients with chronic liverdiseases (such as immune liver disease, chronic hepatitis C, liver cirrhosis, livercancer, etc.), those patients has a higher risk of infection than the general populationduring the epidemic period. More attention should be paid to personal protection anddisease prevention. Vaccination of COVID-19 vaccine can effectively prevent COVID-19virus infection and delay or prevent patients from developing into critical illness andreduce mortality. To evaluate the safety and effectiveness of COVID-19 vaccine in thosepatients with chronic liver diseases, and to guide the COVID-19 vaccination morescientifically, reasonably and effectively, this study was carried out.
Due to the characteristics of liver microcirculation disturbance and immune function
disorder in patients with chronic liver diseases (such as autoimmune liver disease,
chronic hepatitis C, liver cirrhosis, liver cancer, etc.), those patients has a higher
risk of infection than the general population during the epidemic period. More attention
should be paid to personal protection and disease prevention. Vaccination of COVID-19 /
influenza vaccine can effectively prevent COVID-19 / influenza virus infection and delay
or prevent patients from developing into critical illness and reduce mortality. The
safety and effectiveness of COVID-19 / influenza vaccine in this population were
evaluated in order to play a scientific and theoretical supporting role in guiding
COVID-19 vaccination more scientifically, reasonably and effectively. The samples of this
study were collected and tested in the second affiliated Hospital of Chongqing Medical
University. Patients with contraindications for vaccination will be excluded. The
detected indexes included blood routine test, liver function, COVID-19 antibody titer,
antibody duration and other indexes of healthy people (control group) and patients with
chronic liver disease before and after vaccination ( 1, 3, 6, 12 months after
vaccination). The adverse reactions related to the vaccine were recorded.
Biological: SARS-COV-2 VACCINE
the antibody titer and adverse reactions were observed.
Inclusion Criteria:
1. Healthy group were as follows: no history of hepatitis, no history of liver
cirrhosis, no history of liver cancer and receiving the whole-course COVID-19
vaccination.
2. Patients with chronic liver disease diagnosed clinically or pathologically and
receiving the whole-course COVID-19 vaccination.
Exclusion Criteria:
1. Patients previously diagnosed or with a history of contact with confirmed cases
2. Patients with contraindications for vaccination.
The second affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing, China
Investigator: DACHUAN CAI, PH D
Contact: 18323409779
597521685@qq.com
DACHUAN CAI, PH D
18323409779
597521685@qq.com
DAZHI ZHANG, PH D
13452382818
dzhzhang@yahoo.com
Hong Ren, PH D, Principal Investigator
The Second Affiliated Hospital of Chongqing Medical University